• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patient Education Driving BTK Inhibitor Treatment Adherence

Opinion
Video

The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.

The group discusses considerations for educating and empowering patients receiving Bruton tyrosine kinase inhibitor (BTKi) therapy. As BTKis are given continuously long term, Dr Jacobs conceptualizes treatment as a marathon for patients. He emphasizes being upfront about common adverse effects and setting the expectation that doses can be reduced to mitigate toxicities without losing efficacy. This encourages patients to promptly communicate issues rather than try to push through them.

The experts recommend a patient-centered, shared decision-making approach involving the full care team, including pharmacy and nursing, to provide context and resources to help patients work through any adverse effects. Monitoring abandonment rates is also important to ensure patients from all backgrounds can remain on these long-term therapies. Effective patient education and support systems are crucial to facilitate optimal adherence throughout BTKi treatment.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Screenshot of Angela Jia, MD, PhD, during a video interview
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Screenshot of Yuzhi Wang, MD, in a video interview
Dr Chris Pagnani
Stephanie L. Graff, MD, an expert on breast cancer
Stephanie L. Graff, MD, an expert on breast cancer
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.